SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Anika Therapeutics, Inc. – ‘10-Q’ for 6/30/17

On:  Friday, 7/28/17, at 4:06pm ET   ·   For:  6/30/17   ·   Accession #:  1171843-17-4447   ·   File #:  1-14027

Previous ‘10-Q’:  ‘10-Q’ on 5/4/17 for 3/31/17   ·   Next:  ‘10-Q’ on 10/27/17 for 9/30/17   ·   Latest:  ‘10-Q’ on 11/3/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/28/17  Anika Therapeutics, Inc.          10-Q        6/30/17   62:2.7M                                   Globenewswire Inc./FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    218K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
11: R1          Document And Entity Information                     HTML     45K 
12: R2          Condensed Consolidated Balance Sheets (Current      HTML     92K 
                Period Unaudited)                                                
13: R3          Condensed Consolidated Balance Sheets (Current      HTML     38K 
                Period Unaudited) (Parentheticals)                               
14: R4          Condensed Consolidated Statements of Operations     HTML     75K 
                and Comprehensive Income (Unaudited)                             
15: R5          Condensed Consolidated Statements of Cash Flows     HTML     96K 
                (Unaudited)                                                      
16: R6          Note 1 - Nature of Business                         HTML     23K 
17: R7          Note 2 - Basis of Presentation                      HTML     27K 
18: R8          Note 3 - Recent Accounting Pronouncements           HTML     36K 
19: R9          Note 4 - Investments                                HTML     23K 
20: R10         Note 5 - Fair Value Measurements                    HTML     45K 
21: R11         Note 6 - Equity Incentive Plan                      HTML     46K 
22: R12         Note 7 - Earnings Per Share ("Eps")                 HTML     35K 
23: R13         Note 8 - Inventories                                HTML     25K 
24: R14         Note 9 - Intangible Assets                          HTML     39K 
25: R15         Note 10 - Goodwill                                  HTML     25K 
26: R16         Note 11 - Accrued Expenses                          HTML     28K 
27: R17         Note 12 - Commitments and Contingencies             HTML     24K 
28: R18         Note 13 - Leases                                    HTML     25K 
29: R19         Note 14 - Income Taxes                              HTML     29K 
30: R20         Note 15 - Depuy Synthes Mitek Sports Medicine       HTML     22K 
                Monovisc Agreement                                               
31: R21         Note 16 - Segment and Geographic Information        HTML     50K 
32: R22         Note 5 - Fair Value Measurements (Tables)           HTML     41K 
33: R23         Note 6 - Equity Incentive Plan (Tables)             HTML     37K 
34: R24         Note 7 - Earnings Per Share ("Eps") (Tables)        HTML     28K 
35: R25         Note 8 - Inventories (Tables)                       HTML     26K 
36: R26         Note 9 - Intangible Assets (Tables)                 HTML     34K 
37: R27         Note 10 - Goodwill (Tables)                         HTML     24K 
38: R28         Note 11 - Accrued Expenses (Tables)                 HTML     27K 
39: R29         Note 16 - Segment and Geographic Information        HTML     51K 
                (Tables)                                                         
40: R30         Note 3 - Recent Accounting Pronouncements (Details  HTML     21K 
                Textual)                                                         
41: R31         Note 4 - Investments (Details Textual)              HTML     23K 
42: R32         Note 5 - Fair Value Measurements - Fair Value of    HTML     37K 
                Financial Instruments (Details)                                  
43: R33         Note 6 - Equity Incentive Plan (Details Textual)    HTML     42K 
44: R34         Note 6 - Equity Incentive Plan - Assumptions Used   HTML     31K 
                to Estimate Fair Value of Stock Options and Stock                
                Appreciation Rights Awards (Details)                             
45: R35         Note 6 - Equity Incentive Plan - Total Stock-based  HTML     26K 
                Compensation Expense (Details)                                   
46: R36         Note 7 - Earnings Per Share ("Eps") (Details        HTML     42K 
                Textual)                                                         
47: R37         Note 7 - Earnings Per Share ("EPS") - Basic and     HTML     27K 
                Diluted Earnings Per Share (Details)                             
48: R38         Note 8 - Inventories - Inventories (Details)        HTML     28K 
49: R39         Note 9 - Intangible Assets (Details Textual)        HTML     20K 
50: R40         Note 9 - Intangible Assets - Intangible Assets      HTML     42K 
                (Details)                                                        
51: R41         Note 10 - Goodwill - Changes in the Carrying Value  HTML     22K 
                of Goodwill (Details)                                            
52: R42         Note 11 - Accrued Expenses - Accrued Expenses       HTML     37K 
                (Details)                                                        
53: R43         Note 12 - Commitments and Contingencies (Details    HTML     20K 
                Textual)                                                         
54: R44         Note 13 - Leases (Details Textual)                  HTML     37K 
55: R45         Note 14 - Income Taxes (Details Textual)            HTML     33K 
56: R46         Note 15 - Depuy Synthes Mitek Sports Medicine       HTML     24K 
                Monovisc Agreement (Details Textual)                             
57: R47         Note 16 - Segment and Geographic Information        HTML     18K 
                (Details Textual)                                                
58: R48         Note 16 - Segment and Geographic Information -      HTML     27K 
                Product Revenue by Product Group (Details)                       
59: R49         Note 16 - Segment and Geographic Information -      HTML     28K 
                Total Revenue by Geographic Location (Details)                   
61: XML         IDEA XML File -- Filing Summary                      XML    108K 
60: EXCEL       IDEA Workbook of Financial Reports                  XLSX     46K 
 5: EX-101.INS  XBRL Instance -- anik-20170630                       XML    758K 
 7: EX-101.CAL  XBRL Calculations -- anik-20170630_cal               XML    102K 
 8: EX-101.DEF  XBRL Definitions -- anik-20170630_def                XML    722K 
 9: EX-101.LAB  XBRL Labels -- anik-20170630_lab                     XML    564K 
10: EX-101.PRE  XBRL Presentations -- anik-20170630_pre              XML    744K 
 6: EX-101.SCH  XBRL Schema -- anik-20170630                         XSD    126K 
62: ZIP         XBRL Zipped Folder -- 0001171843-17-004447-xbrl      Zip     80K 




        
Filing Submission 0001171843-17-004447 – SGML Text

Original SGML Text submitted by:  Globenewswire Inc./FA  (as Filing Agent) 

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 3, 5:55:38.2pm ET